The study drug is a potential new treatment for various forms of pulmonary fibrosis, which are lung conditions that cause scar tissue to develop in the lungs.
The study drug is a nebulised treatment. A nebuliser device will convert the liquid drug into a mist, which participants will inhale via a mask that is placed over the nose and mouth for 4 to 9 minutes.
The study drug would provide new treatment options for various conditions such as idiopathic pulmonary fibrosis, progressive fibrotic interstitial lung disease, and fibrosis (scar tissue) that has developed in the lungs after COVID-19 infections.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!